Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated May 9, 2025, discloses insider trading activity in compliance with Article 19 of Regulation No. 596/2014 on market abuse. The report covers transactions executed on May 7, 2025, by an executive of the company, a global healthcare leader headquartered in Denmark focused on defeating serious chronic diseases.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory disclosure of share transactions.
| Transaction Type | Instrument | Volume | Total Value (DKK) |
|---|---|---|---|
| Sale | Novo Nordisk B Shares | 40,000 | 18,021,100 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely details a reduction in shareholding by an executive.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a routine disclosure of a transaction by Ludovic Helfgott, Executive Vice President, who sold 40,000 shares on Nasdaq Copenhagen at varying prices between DKK 444.59 and DKK 467.88.
Key Facts for Investor Verification
- Insider Sale: Executive Vice President Ludovic Helfgott sold 40,000 Novo Nordisk B shares.
- Transaction Date: May 7, 2025.
- Transaction Value: Approximately DKK 18.02 million.
- Market: Nasdaq Copenhagen.
- Financial Data: This filing provides no quarterly or annual financial results; investors should refer to the company's Form 20-F or quarterly reports for financial metrics.